Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma

E-ISSN： 1096-8652|361-8609|10|888-891

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.361-8609, Iss.10, 2015-10, pp. : 888-891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard‐risk cytogenetics

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 523-531

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 140-145

Karger

Access to resources Recommend Favorite

Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 647-652

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum Growth Differentiation Factor 15 Levels in Newly Diagnosed Multiple Myeloma Patients

Acta Haematologica, Vol. 131, Iss. 3, 2013-11 ,pp. : 173-178

Karger

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite